Tech Company Inital Public Offerings
Pandion Therapeutics IPO
Pandion Therapeutics was acquired by . Shares were listed on 7/17/2020.
Transaction Overview
Company Name
Announced On
7/17/2020
Transaction Type
IPO
Amount
$153,000,000
Proceeds Purpose
Use of proceeds for the Pandion Therapeutics IPO are outlined in the company's S1 filing.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
610 Main St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory disease and organ transplants.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rahul Kakkar
Chief Operating Officer
Ed Freedman
Chief Scientific Officer
Jo Viney
VP - Bus. Development
Vikas Goyal
VP - Engineering
Hussam Shaheen
Browse more venture capital transactions:
Prev: 7/17/2020: Openpath venture capital transaction
Next: 7/17/2020: Enduvo venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to record tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs